Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News BioLineRx ADS Representing 15 Ord Shs BLRX

Healthcare Biotechnology
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform ,... see more

Recent & Breaking News (NDAQ:BLRX)

BioLineRx Announces Underwritten Public Offering of its American Depositary Shares

PR Newswire March 30, 2017

BioLineRx's AGI-134 to be Presented at AACR 2017

PR Newswire March 27, 2017

BioLineRx Reports Year End 2016 Financial Results

PR Newswire March 23, 2017

BioLineRx Announces Acquisition of Agalimmune Ltd. to Accelerate Expansion of Immuno-Oncology Pipeline

PR Newswire March 23, 2017

BioLineRx Provides Update on Phase 2 Open-Label Study for BL-8040 as Novel Stem Cell Mobilization Treatment

PR Newswire March 20, 2017

BioLineRx to Report Annual 2016 Results on March 23, 2017

PR Newswire March 16, 2017

BioLineRx to Present at 2017 BIO CEO & Investor Conference in New York on February 14

PR Newswire February 7, 2017

BioLineRx Announces Initiation of Immuno-Oncology Phase 2 Study to Investigate Combination of BL-8040 and KEYTRUDA® for Pancreatic Cancer

PR Newswire January 17, 2017

BioLineRx to Present at Biotech Showcase 2017 Conference in San Francisco

PR Newswire January 4, 2017

15 Biggest Mid-Day Gainers For Monday

Benzinga.com  December 5, 2016

18 Stocks Moving In Monday's Pre-Market Session

Benzinga.com  December 5, 2016

BioLineRx Presents Positive Phase 2a AML Study and Mechanism-of-Action Data for BL-8040 Oncology Platform at ASH 2016

PR Newswire December 5, 2016

BioLineRx Reports Third Quarter 2016 Financial Results

PR Newswire November 22, 2016

BioLineRx In-licenses Novel Anti-Inflammatory Treatment for Dry Eye Syndrome Under Strategic Collaboration with Major Global Pharmaceutical Company

PR Newswire November 21, 2016

BioLineRx to Report Third Quarter Results on November 22, 2016

PR Newswire November 15, 2016

BioLineRx Discloses Positive Correlative Data from Phase 2a AML Study and Mechanism-of-Action Data for BL-8040 Oncology Platform at ASH 2016

PR Newswire November 3, 2016

BioLineRx Announces Acceptance of BL-8040 Abstracts for Oral and Poster Presentations at 58th American Society of Hematology (ASH) Annual Meeting

PR Newswire October 5, 2016

BioLineRx Announces In-licensing of Novel Treatment for Liver Failure Conditions Under Strategic Collaboration

PR Newswire September 23, 2016

BioLineRx Ltd. Presents Corporate Objectives at Investor Breakfast Meeting in NY

PR Newswire September 22, 2016

18 Biggest Mid-Day Gainers For Wednesday

Benzinga.com  September 7, 2016